319 related articles for article (PubMed ID: 19698059)
1. Reconsideration of severe hypoglycemic events in the treat-to-target trial.
Dailey G; Strange P; Riddle M
Diabetes Technol Ther; 2009 Aug; 11(8):477-9. PubMed ID: 19698059
[TBL] [Abstract][Full Text] [Related]
2. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
Pan CY; Sinnassamy P; Chung KD; Kim KW;
Diabetes Res Clin Pract; 2007 Apr; 76(1):111-8. PubMed ID: 17011662
[TBL] [Abstract][Full Text] [Related]
3. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
Rosenstock J; Dailey G; Massi-Benedetti M; Fritsche A; Lin Z; Salzman A
Diabetes Care; 2005 Apr; 28(4):950-5. PubMed ID: 15793205
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
[TBL] [Abstract][Full Text] [Related]
5. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
Eliaschewitz FG; Calvo C; Valbuena H; Ruiz M; Aschner P; Villena J; Ramirez LA; Jimenez J;
Arch Med Res; 2006 May; 37(4):495-501. PubMed ID: 16715577
[TBL] [Abstract][Full Text] [Related]
6. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
Rosenstock J; Fonseca V; Schinzel S; Dain MP; Mullins P; Riddle M
J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
[TBL] [Abstract][Full Text] [Related]
7. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
Duckworth W; Davis SN
J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
[TBL] [Abstract][Full Text] [Related]
9. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes.
Schober E; Schoenle E; Van Dyk J; Wernicke-Panten K;
Diabetes Care; 2001 Nov; 24(11):2005-6. PubMed ID: 11679478
[No Abstract] [Full Text] [Related]
10. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
Dailey G; Strange P
Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemia with insulin in post-transplant diabetes mellitus.
Chandra A; Rao N; Pooniya V; Singh A
Transpl Immunol; 2023 Jun; 78():101833. PubMed ID: 37024062
[TBL] [Abstract][Full Text] [Related]
12. Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the "diabetes mellitus model".
Maxion-Bergemann S; Huppertz E; Jacobs LD; Müller E; Walleser S
Int J Clin Pharmacol Ther; 2005 Jun; 43(6):271-81. PubMed ID: 15968884
[TBL] [Abstract][Full Text] [Related]
13. Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction.
Berard L; Cameron B; Woo V; Stewart J
Can J Diabetes; 2015 Aug; 39(4):296-301. PubMed ID: 25819531
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Hypoglycemia and Safety Outcomes With Long-Acting Insulins Versus Insulin NPH in Pregestational and Gestational Diabetes.
Sleeman A; Odom J; Schellinger M
Ann Pharmacother; 2020 Jul; 54(7):669-675. PubMed ID: 31893932
[No Abstract] [Full Text] [Related]
15. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
Garg SK; Paul JM; Karsten JI; Menditto L; Gottlieb PA
Diabetes Technol Ther; 2004 Oct; 6(5):589-95. PubMed ID: 15628812
[TBL] [Abstract][Full Text] [Related]
16. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
[TBL] [Abstract][Full Text] [Related]
17. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
Yeldandi RR; Lurie A; Baldwin D
Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
[TBL] [Abstract][Full Text] [Related]
18. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial.
Umpierrez GE; Jones S; Smiley D; Mulligan P; Keyler T; Temponi A; Semakula C; Umpierrez D; Peng L; Cerón M; Robalino G
Diabetes Care; 2009 Jul; 32(7):1164-9. PubMed ID: 19366972
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
[TBL] [Abstract][Full Text] [Related]
20. Basal insulins: Pharmacological properties and patient perspectives.
Abrahamson MJ
Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
